- Home
- IMMX vs UCL Comparison
IMMX vs UCL Comparison
Compare IMMX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- UCL
- Stock Information
- Founded
- IMMX 2014
- UCL 2014
- Country
- IMMX United States
- UCL Hong Kong
- Employees
- IMMX N/A
- UCL N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- UCL Telecommunications Equipment
- Sector
- IMMX Health Care
- UCL Consumer Discretionary
- Exchange
- IMMX Nasdaq
- UCL Nasdaq
- Market Cap
- IMMX 61.1M
- UCL 70.6M
- IPO Year
- IMMX 2021
- UCL 2020
- Fundamental
- Price
- IMMX $2.65
- UCL $1.92
- Analyst Decision
- IMMX Strong Buy
- UCL
- Analyst Count
- IMMX 1
- UCL 0
- Target Price
- IMMX $7.00
- UCL N/A
- AVG Volume (30 Days)
- IMMX 137.1K
- UCL 51.0K
- Earning Date
- IMMX 08-11-2025
- UCL 08-13-2025
- Dividend Yield
- IMMX N/A
- UCL N/A
- EPS Growth
- IMMX N/A
- UCL N/A
- EPS
- IMMX N/A
- UCL 0.09
- Revenue
- IMMX N/A
- UCL $92,256,000.00
- Revenue This Year
- IMMX N/A
- UCL $6.09
- Revenue Next Year
- IMMX N/A
- UCL $7.01
- P/E Ratio
- IMMX N/A
- UCL $20.26
- Revenue Growth
- IMMX N/A
- UCL 7.65
- 52 Week Low
- IMMX $1.26
- UCL $0.80
- 52 Week High
- IMMX $3.00
- UCL $3.30
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- UCL 58.25
- Support Level
- IMMX $2.16
- UCL $1.79
- Resistance Level
- IMMX $2.80
- UCL $1.96
- Average True Range (ATR)
- IMMX 0.17
- UCL 0.14
- MACD
- IMMX 0.04
- UCL -0.02
- Stochastic Oscillator
- IMMX 80.00
- UCL 33.97
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.